Speaker: Sarah Tasian

0:00:42

Exploring the potential role of immunotherapy in Ph-like ALL and novel targets of interest

0:00:56

Improving therapeutic approaches for patients with Ph-like ALL & the importance of disease biology

0:00:46

An update on targeted therapy in pediatric leukemia

0:01:09

Precision medicine in pediatric ALL

0:01:06

Targeting TCF3-HLF−positive ALL

0:01:23

Azacitidine and venetoclax +/- gemtuzumab ozogamicin in pediatric patients with R/R acute leukemias

0:00:49

Exploring novel treatment strategies for Ph-like ALL

0:00:54

Clinical responses of pediatric patients with R/R acute leukemia treated with aza/ven

0:05:17

Immunotherapy for pediatric AML

0:01:15

Future directions for treating Ph-like ALL subtypes

0:01:00

Clinical screening for Ph-like ALL and trials available to pediatric patients

0:00:49

Gilteritinib and CAR T-cell therapy in high-risk pediatric leukemias

0:01:06

Challenges in treating pediatric leukemias

0:04:58

Diagnostic strategies for Ph-like ALL

0:02:00

Targeted therapy for Ph-like ALL

0:01:09

Pre-clinical activity of ziftomenib in pediatric KMT2A-rearranged ALL

0:01:08

A Phase II study of ruxolitinib with chemotherapy in pediatric patients with Ph-like ALL

0:01:16

Pediatric leukemia at ASCO 2023

0:02:09

Targeting TSLPR in Ph-like and Down syndrome-associated ALL

0:02:29

Phase 1 trials of novel CAR T-cells for leukemia

0:03:08

Diagnostic testing modalities for Ph-like ALL

0:02:24

Addition of TKIs to chemotherapy when treating Ph-like ALL

0:02:17

Blinatumomab and inotuzumab in children with R/R B-ALL

1:33:46

PMNET Forum 2024: Cellular Immunotherapies In Pediatric Care